Font: Financial Modeling Prep • Nov 17, 2026
Medtronic (NYSE: MDT) develops medical technologies for vascular disease, heart rhythm, and surgery. Piper Sandler upgraded Medtronic to Overweight when shares were trading at $102.88. Its $120 price target was 16.64% above that price.
Medtronic plans to acquire privately held Contego Medical, expanding its portfolio of carotid technologies and therapies for peripheral vascular disease. The deal builds on an exclusive U.S. distribution agreement announced in January 2025. Medtronic executive David Moeller says the acquisition strengthens its position in treating carotid artery disease.
Affera and PulseSelect are expanding Medtronic’s heart-rhythm business and driving material revenue growth and opportunities for recurring procedure sales. CMS coverage for its Symplicity Spyral renal denervation treatment removes a commercial barrier and enables access to more than 18 million target U.S. patients with hypertension.
Medtronic’s Hugo robotic surgery platform has received initial U.S. clearance for urologic procedures, with future growth tied to more instruments and procedure approvals. Shares were at $102.88, up $0.02, or 0.02%, and traded between $102.85 and $104.49 during the day.
Medtronic’s 52-week range was $73.31 to $106.33. Its market capitalization was $131.6 billion, and trading volume was 6.73 million shares.
|
LICN§>
Lichen International Limited
|
$0.02
-28.18%
|
|
NVDA§>
NVIDIA Corporation
|
$152.11
-2.15%
|
|
CHSN§>
Chanson International Holding
|
$0.10
-78.66%
|
|
SOXL§>
Direxion Daily Semiconductor Bull 3X ETF
|
$49.12
0.09%
|
|
SVRE§>
SaverOne 2014 Ltd
|
$0.75
82.45%
|
|
SPDN§>
Direxion Daily S&P 500 Bear 1X ETF
|
$8.87
0.00%
|
|
INLF§>
INLIF Limited
|
$0.36
0.72%
|
|
AES§>
The AES Corporation
|
$15.02
0.30%
|
|
AKAN§>
Akanda Corp.
|
$3.76
83.41%
|
|
TQQQ§>
ProShares UltraPro QQQ
|
$52.89
2.08%
|